Clinical Trials

Clinical trials are essential to developing new treatments for the diseases that cause dementia, and to ensuring that these are safe and effective.

For people in the UK to be among the first to benefit from new treatments the UK needs to be a leading location for clinical trials. This is dependent on a number of factors including investment in research and the clinical trials infrastructure and how easy it is for pharmaceutical companies to conduct trials and for new treatments to be approved for use in the healthcare system.

clinical trials participants UK global

ARUK report: The Economic Value of Dementia Research.

clinical trials global uk participation

ARUK report: The Economic Value of Dementia Research.

clinical trials comparison cancer recruitment participants

The Future of Clinical Trials. ARUK report 2021.

research participants perceptions

Dementia Attitudes Monitor (Alzheimer’s Research UK).

cancer stroke coronary heart disease comparison recruitment clinical trial

Parliamentary question for DHSC on clinical trial recruitment.

join dementia research recruitment participants clinical trials

The Future of Clinical Trials. ARUK report 2021.

clinical trials patients recruitment psychiatrists

Are we ready to deliver disease modifying treatments, ARUK report 2021.

research participation recruitment patient

National Audit of Dementia 2021.

recruitment participants patients clinical trials

The Future of Clinical Trials. Alzheimer’s Research UK Report 2021.

Number of participants recruited to NIHR phase 3 trials over 10 years

clinical trials participation compare, comparison cancer phase 3

Parliamentary question for the Department of Health and Social Care.

Involvement in phase 3 clinical trials by country

clinical trials global worldwide phase 3

ClinicalTrials.gov